Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 1
1981 3
1982 1
1984 1
1991 1
1993 2
1994 1
1995 2
2002 1
2005 1
2008 1
2010 1
2015 2
2018 1
2020 1
2021 1
2022 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study.
Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, Ciuleanu TE, Portnoy DC, Van Cutsem E, Grothey A, Prausová J, Garcia-Alfonso P, Yamazaki K, Clingan PR, Lonardi S, Kim TW, Simms L, Chang SC, Nasroulah F; RAISE Study Investigators. Tabernero J, et al. Lancet Oncol. 2015 May;16(5):499-508. doi: 10.1016/S1470-2045(15)70127-0. Epub 2015 Apr 12. Lancet Oncol. 2015. PMID: 25877855 Clinical Trial.
Rapid Inhibitor Discovery by Exploiting Synthetic Lethality.
Muscato JD, Morris HG, Mychack A, Rajagopal M, Baidin V, Hesser AR, Lee W, İnecik K, Wilson LJ, Kraml CM, Meredith TC, Walker S. Muscato JD, et al. J Am Chem Soc. 2022 Mar 2;144(8):3696-3705. doi: 10.1021/jacs.1c12697. Epub 2022 Feb 16. J Am Chem Soc. 2022. PMID: 35170959 Free PMC article.
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
Saad F, Fizazi K, Jinga V, Efstathiou E, Fong PC, Hart LL, Jones R, McDermott R, Wirth M, Suzuki K, MacLean DB, Wang L, Akaza H, Nelson J, Scher HI, Dreicer R, Webb IJ, de Wit R; ELM-PC 4 investigators. Saad F, et al. Lancet Oncol. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18. Lancet Oncol. 2015. PMID: 25701170 Clinical Trial.
Peritoneal fluid cell populations in infertility patients.
Haney AF, Muscato JJ, Weinberg JB. Haney AF, et al. Among authors: muscato jj. Fertil Steril. 1981 Jun;35(6):696-8. doi: 10.1016/s0015-0282(16)45567-6. Fertil Steril. 1981. PMID: 7195828 Free article. No abstract available.
Phase I study of a 3-drug regimen of gemcitabine/cisplatin/pemetrexed in patients with metastatic transitional cell carcinoma of the urothelium.
Hutson TE, Vukelja S, Atienza D, Awasthi S, Delaune R, Deutsch M, Dien PY, Gregory TF, Kolodziej MJ, Muscato JJ, Raju RN, Ruxer RL Jr, Mull S, Ilegbodu D, Hood K, Nicol S, Berry W. Hutson TE, et al. Among authors: muscato jj. Invest New Drugs. 2008 Apr;26(2):151-8. doi: 10.1007/s10637-007-9111-2. Epub 2008 Jan 31. Invest New Drugs. 2008. PMID: 18236006 Clinical Trial.
21 results